Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)
Close on Nov 18, 2026Market cap $528.94MP/E –Yield –
Myriad Genetics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Myriad Genetics's price to sales ratio was 0.7× on Nov 11, 2026, against 0.9× a year earlier. Over the last 5 years it ranged from 0.3× to 3.3×, with a median of 2.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.7× | −0.0 |
| 2025 | Dec 31, 2025 | 0.7× | −0.8 |
| 2024 | Dec 31, 2024 | 1.5× | −0.6 |
| 2023 | Dec 29, 2023 | 2.1× | +0.3 |
| 2022 | Dec 30, 2022 | 1.8× | −1.4 |
| 2021 | Dec 31, 2021 | 3.2× | +0.9 |
| 2020 | Dec 31, 2020 | 2.3× | −0.1 |
| 2019 | Dec 31, 2019 | 2.4× | −0.4 |
| 2018 | Dec 31, 2018 | 2.8× | −0.3 |
| 2017 | Dec 29, 2017 | 3.1× | +1.5 |
| 2016 | Dec 30, 2016 | 1.5× | −2.5 |
| 2015 | Dec 31, 2015 | 4.1× | +0.7 |
| 2014 | Dec 31, 2014 | 3.3× | +1.0 |
| 2013 | Dec 31, 2013 | 2.4× | −1.9 |
| 2012 | Dec 31, 2012 | 4.3× | +0.1 |
| 2011 | Dec 30, 2011 | 4.2× | −1.5 |
| 2010 | Dec 31, 2010 | 5.7× | −2.2 |
| 2009 | Dec 31, 2009 | 7.9× | – |
See a number that looks wrong?